Effects of danazol, gonadotropin-releasing hormone agonist, and a combination of danazol and gonadotropin-releasing hormone agonist on experimental endometriosis

Sakata M, Masahiro Sakata, M. Sakata, Terakawa N, N Terakawa, Naoki Terakawa, T Mizutani, Mizutani T, Takahiro Mizutani, Tanizawa O, Osamu Tanizawa, O. Tanizawa, K Matsumoto, Matsumoto K, Keishi Matsumoto, N Terada, Nobuyuki Terada, Terada N, K Sudo, Katsuichi Sudo, Sudo K
American journal of obstetrics and gynecology · 1990 · vol. 163(5) , pp. 1679–1684 · doi:10.1016/0002-9378(90)90650-v · PMID:2122726 · W2005455233
article OA: closed CC0 ⤵ 20 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated the effects of danazol, a GnRH agonist, and their combination on experimental endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Effects of danazol, gonadotropin-releasing hormone agonist (leuprolide), and danazol-leuprolide combination on experimental endometriosis were evaluated in female rats. A complete resorption of the fluid and a marked decrease in the volume of endometrium autotransplanted under the renal capsule were found after castration (1.4 +/- 0.1 mm3 in castrated, n = 14, vs 26.7 +/- 5.6 mm3 in intact control, n = 16). Histologic examination indicated atrophy and regression of the endometrial explant. These atrophic changes of endometrial explant were also induced by danazol, leuprolide, and the combination treatment. However, the volume of explants after combination therapy with danazol and leuprolide (1.8 +/- 1.0 mm3, n = 17) was significantly less than that after therapy with danazol (11.6 +/- 2.8 mm3, n = 20) or leuprolide alone (5.9 +/- 1.4 mm3, n = 24). The combination therapy (16/17) was also shown to be superior to danazol (9/20) or leuprolide alone (14/24) to induce the regression of fluid in experimental endometriosis. As expected, administration of leuprolide decreased the serum estradiol level, but use of danazol did not. These findings suggest that a combination therapy of danazol and gonadotropin-releasing hormone agonist, which show different modes of action, may be a potential modality in treatment of patients with advanced endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Danazol Endometriosis Gonadotropin-Releasing Hormone Analysis of Variance Animals Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Chi-Square Distribution Danazol Danazol Endometriosis Endometriosis Endometriosis Estradiol Estradiol Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Cited by (20)

Source provenance

europepmc
last seen: 2026-08-06T06:07:45.168820+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:05.481982+00:00
License: CC0 · commercial use OK